• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human F-box only protein 38 (FBXO38), Truncated

ACP16456

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP16456 Target NameFBXO38
Target SynonymsFBXO38; SP329F-box only protein 38FormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Protein LengthPartial
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ6PIJ6
Background Information
  • Uniprot Id

    Q6PIJ6

  • Target Species

    Human

  • Target Name

    FBXO38

  • Target Full Name

    F-box only protein 38

  • Target Function

    Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of PDCD1/PD-1, thereby regulating T-cells-mediated immunity. Required for anti-tumor activity of T-cells by promoting the degradation of PDCD1/PD-1; the PDCD1-mediated inhibitory pathway being exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival. May indirectly stimulate the activity of transcription factor KLF7, a regulator of neuronal differentiation, without promoting KLF7 ubiquitination.

  • Target Involvement

    Neuronopathy, distal hereditary motor, 2D (HMN2D)

  • Target Subcellular Location

    Cytoplasm, cytosol. Nucleus.

  • Target Synonyms

    FBXO38; SP329F-box only protein 38

Inquire Recombinant Human F-box only protein 38 (FBXO38), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification